Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has ... knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.